
  
    
      
        Introduction_NNP
        Alzheimer_NNP disease_NN is_VBZ the_DT leading_VBG cause_NN of_IN dementia_NN among_IN the_DT elderly_JJ and_CC is_VBZ
        characterized_VBN by_IN accumulation_NN of_IN extracellular_NN and_CC vascular_NN amyloid_NN in_IN the_DT brain_NN [_NN 1_CD ]_NN ._.
        Amyloid_NNP deposits_NNS are_VBP composed_VBN of_IN the_DT amyloid-β_JJ peptide_NN (_( Aβ_NNP )_) ,_, a_DT 4_CD -_: kDa_NN peptide_NN released_VBN
        during_IN “ amyloidogenic_JJ” proteolytic_JJ processing_NN of_IN the_DT Alzheimer_NNP Aβ_NNP precursor_NN protein_NN (_( APP_NNP )_)
        [_NN 2_CD ]_NN ._. APP_NNP can_MD also_RB be_VB cleaved_JJ by_IN the_DT nonamyloidogenic_JJ α-secretases_JJ ,_, a_DT disintegrin_NN and_CC
        metalloproteinase_NN 10_CD (_( ADAM-_NNP 10_CD )_) and_CC ADAM-_NNP 17_CD [_NN 3_CD ]_NN ,_, in_IN a_DT reaction_NN that_WDT is_VBZ believed_VBN to_TO occur_VB
        primarily_RB on_IN the_DT plasma_NN membrane_NN [_NN 4_CD ]_NN and_CC is_VBZ known_VBN as_IN “ ectodomain_NN shedding_NN ._.”
        α-_NN Secretase-type_NNP ectodomain_NN shedding_VBG divides_VBZ the_DT Aβ_NNP domain_NN of_IN APP_NNP ,_, thereby_RB generating_NN
        α-secretase-cleaved_JJ soluble_JJ APP_NNP ectodomain_NN (_( sAPP_NN
        α_NN )_) [_NN 4_CD ]_NN ._. This_DT reaction_NN can_MD be_VB stimulated_VBN by_IN activation_NN of_IN protein_NN kinase_NN
        C_NNP (_( PKC_NNP )_) or_CC extracellular-signal-regulated_JJ protein_NN kinases_NNS (_( ERKs_NNP )_) [_NN 5_CD ,_, 6_CD ,_, 7_CD ]_NN or_CC by_IN inactivation_NN
        of_IN protein_NN phosphatase_NN 1_CD or_CC 2_CD A_DT [_NN 5_CD ]_NN ._.
        Reports_NNS from_IN retrospective_NN analyses_NNS suggest_VBP that_IN the_DT statin_NN class_NN of_IN
        cholesterol-lowering_JJ HMGCoA_NNP reductase_NN inhibitors_NNS may_MD lower_VB the_DT risk_NN for_IN Alzheimer_NNP disease_NN
        by_IN as_RB much_JJ as_IN 70_CD %_NN [_NN 8_CD ,_, 9_CD ,_, 10_CD ,_, 11_CD ]_NN ._. Studies_NNS in_IN wild-type_JJ guinea_NN pigs_NNS and_CC in_IN plaque-forming_JJ
        transgenic_JJ mice_NNS have_VBP demonstrated_VBN that_IN chronic_JJ statin_NN treatment_NN can_MD attenuate_NN cerebral_JJ
        amyloidosis_NNS [_NN 12_CD ,_, 13_CD ]_NN ,_, suggesting_VBG that_IN statins_NNS may_MD exert_VB their_PRP$ risk-reducing_JJ effects_NNS ,_, at_IN
        least_JJS in_IN part_NN ,_, by_IN modulating_VBG APP_NNP metabolism_NN ._. In_IN cell_NN culture_NN ,_, lovastatin_NN and_CC simvastatin_NN
        decrease_VBP the_DT release_NN of_IN Aβ_NNP by_IN rat_NN hippocampal_NN neurons_NNS [_NN 12_CD ,_, 14_CD ]_NN while_IN activating_VBG
        α-secretase-type_JJ ectodomain_NN shedding_VBG [_NN 15_CD ,_, 16_CD ]_NN ._. However_RB ,_, the_DT molecular_JJ mechanisms_NNS by_IN which_WDT
        statins_NNS modulate_VBP ectodomain_NN shedding_VBG remain_VB to_TO be_VB elucidated_JJ [_NN 17_CD ,_, 18_CD ]_NN ._.
        Statin_NNP effects_NNS on_IN APP_NNP metabolism_NN are_VBP ,_, to_TO some_DT extent_NN ,_, attributable_JJ to_TO cholesterol_NN
        lowering_VBG ,_, but_CC statin_NN actions_NNS on_IN APP_NNP may_MD also_RB involve_VB cholesterol-independent_JJ actions_NNS [_NN 19_CD ]_NN ._.
        Reduction_NNP in_IN synthesis_NN of_IN mevalonate_NN leads_VBZ to_TO decreased_VBN generation_NN of_IN a_DT number_NN of_IN
        isoprenoid_NN lipid_NN derivatives_NNS ._. Isoprenoids_NNP ,_, such_JJ as_IN farnesyl_NN pyrophosphate_NN and_CC
        geranylgeranyl_NN pyrophosphate_NN ,_, are_VBP 15_CD -_: or_CC 20_CD -_: carbon_NN lipid_NN moieties_NNS ._. Through_IN the_DT action_NN of_IN
        farnesyl_NN transferases_NNS and_CC type_NN I_PRP geranylgeranyl_NN transferases_NNS ,_, isoprenoids_NNS are_VBP attached_VBN to_TO
        the_DT amino_JJ acid_NN sequence_NN Cys-_NNP Ala-_NNP Ala-_NNP Xaa_NNP (_(“ CAAX_NNP” )_) at_IN the_DT C-_NNP terminus_JJ of_IN the_DT Rho_NNP family_NN of_IN
        GTPases_NNP [_NN 20_CD ]_NN ._. These_DT posttranslational_NN lipid_NN modifications_NNS are_VBP essential_JJ for_IN attachment_NN of_IN
        the_DT GTPases_NNP to_TO the_DT cytosolic_JJ face_NN of_IN intracellular_NN vesicles_NNS and_CC /_NN or_CC to_TO the_DT cytosolic_JJ leaflet_NN
        of_IN the_DT plasma_NN membrane_NN ,_, thereby_RB specifying_VBG subcellular_NN targets_NNS for_IN GTPase_NNP action_NN (_( s_VBZ )_) ._.
        Some_DT members_NNS of_IN the_DT Rho_NNP GTPase_NNP family_NN exert_VB their_PRP$ actions_NNS through_IN modulation_NN of_IN protein_NN
        kinase_NN activities_NNS ._. One_CD of_IN the_DT best_RBS characterized_VBN is_VBZ Rho-associated_NNP protein_NN kinase_NN 1_CD (_( ROCK_NNP 1_CD ,_,
        also_RB called_VBN ROKβ_NNP )_) ._. ROCK_NNP 1_CD is_VBZ a_DT serine_NN /_NN threonine_NN kinase_NN with_IN an_DT apparent_JJ mass_NN of_IN 160_CD kDa_NN that_WDT
        can_MD be_VB activated_VBN by_IN either_DT RhoA_NNP or_CC RhoB_NNP [_NN 21_CD ,_, 22_CD ,_, 23_CD ]_NN ._. Structurally_NNP ,_, the_DT ROCK_NNP 1_CD N-_NNP terminus_JJ
        contains_VBZ the_DT protein_NN kinase_NN domain_NN ,_, while_IN the_DT C-_NNP terminus_JJ has_VBZ both_DT a_DT Rho-binding_NNP domain_NN and_CC
        a_DT pleckstrin_NN homology_NN domain_NN ,_, either_CC of_IN which_WDT can_MD modulate_VBP protein–protein_NN interactions_NNS ._. In_IN
        the_DT inactive_JJ state_NN ,_, the_DT Rho-binding_NNP domain_NN and_CC the_DT pleckstrin_NN homology_NN domain_NN form_NN an_DT
        autoinhibitory_NN loop_NN by_IN binding_JJ and_CC blocking_VBG the_DT kinase_NN domain_NN at_IN the_DT N-_NNP terminus_JJ of_IN the_DT
        molecule_NN ._. Activation_NNP of_IN ROCK_NNP 1_CD occurs_VBZ when_WRB a_DT Rho_NNP protein_NN binds_NNS to_TO the_DT Rho-binding_NNP domain_NN ,_,
        causing_VBG a_DT conformational_NN change_NN that_WDT opens_VBZ the_DT kinase_NN domain_NN for_IN the_DT phosphorylation_NN of_IN
        downstream_JJ effectors_NNS [_NN 23_CD ]_NN ._. Once_RB activated_VBN ,_, ROCK_NNP 1_CD phosphorylates_NNS several_JJ substrates_NNS ,_,
        including_VBG myosin_NN light_JJ chain_NN phosphatase_NN ,_, LIM_NNP kinases_NNS (_( Lin_NNP 11_CD ,_, Isl_NNP 1_CD ,_, and_CC Mec_NNP 3_LS )_) ,_, and_CC
        ezrin-radixin-moesin_JJ proteins_NNS [_NN 24_CD ,_, 25_CD ,_, 26_CD ,_, 27_CD ]_NN ._. ROCK_NNP 1_CD has_VBZ recently_RB been_VBN implicated_VBN in_IN
        modifying_VBG the_DT site_NN of_IN substrate_NN cleavage_NN by_IN APP_NNP γ-secretase_JJ [_NN 28_CD ]_NN ,_, perhaps_RB acting_VBG via_IN
        ROCK_NNP 1_CD -_: dependent_JJ phosphorylation_NN of_IN a_DT component_NN of_IN the_DT γ-secretase_JJ enzyme_NN complex_JJ ._.
        In_IN the_DT current_JJ study_NN ,_, we_PRP demonstrate_VBP that_DT activation_NN of_IN sAPP_NN
        α_NN shedding_VBG from_IN cultured_JJ cells_NNS by_IN atorvastatin_NN or_CC simvastatin_NN involves_VBZ
        isoprenoid-mediated_JJ protein_NN phosphorylation_NN ._. Treatment_NNP of_IN cells_NNS with_IN a_DT farnesyl_NN transferase_NN
        inhibitor_NN or_CC expression_NN of_IN a_DT dominant_JJ negative_JJ (_( DN_NNP )_) ROCK_NNP 1_CD molecule_NN led_VBN to_TO enhanced_JJ sAPP_NN
        α_NN shedding_NN ,_, supporting_VBG the_DT notion_NN that_IN shedding_VBG is_VBZ modulated_JJ by_IN the_DT
        isoprenoid_NN pathway_NN ._. Transfection_NNP with_IN the_DT cDNA_NN for_IN a_DT constitutively_RB active_JJ (_( CA_NNP )_) ROCK_NNP 1_CD
        molecule_NN led_VBN to_TO inhibition_NN of_IN statin-activated_JJ sAPP_NN
        α_NN shedding_NN ._. These_DT results_NNS raise_VBP the_DT possibility_NN that_IN the_DT apparent_JJ
        beneficial_JJ effect_NN of_IN statins_NNS in_IN the_DT prevention_NN of_IN Alzheimer_NNP disease_NN could_MD be_VB ,_, at_IN least_JJS in_IN
        part_NN ,_, mediated_JJ by_IN isoprenoid_NN modulation_NN of_IN APP_NNP metabolism_NN ._.
      
      
        Methods_NNP
        
          Reagents_NNP
          The_DT APP_NNP C-_NNP terminal_NN specific_JJ polyclonal_NN antibody_NN 369_CD [_NN 29_CD ]_NN was_VBD used_VBN to_TO detect_VB
          full-length_JJ APP_NNP and_CC its_PRP$ C-_NNP terminal_NN fragments_NNS ._. Monoclonal_NNP antibody_NN 6_CD E_NNP 10_CD against_IN residues_NNS
          1_CD –_NN 16_CD of_IN human_JJ Aβ_NNP (_( Signet_NNP ,_, Dedham_NNP ,_, Massachusetts_NNP ,_, United_NNP States_NNPS )_) was_VBD used_VBN to_TO detect_VB human_JJ
          holoAPP_NN or_CC sAPP_NN
          α_NN ._. Anti-_NNP ROCK_NNP 1_CD antibody_NN was_VBD purchased_VBN from_IN Chemicon_NNP (_( Temecula_NNP ,_,
          California_NNP ,_, United_NNP States_NNPS )_) ._. Streptavidin-antibody_NNP HRP-conjugated_NNP C-M_NNP yc_NN antibody_NN 9_CD E_NNP 10_CD ,_,
          mevalonic_JJ acid_NN ,_, arachidonic_JJ acid_NN ,_, and_CC phenylarsine_NN oxide_NN were_VBD purchased_VBN from_IN Sigma_NNP (_( St_NNP ._.
          Louis_NNP ,_, Missouri_NNP ,_, United_NNP States_NNPS )_) ._. Atorvastatin_NNP was_VBD obtained_VBN from_IN Pfizer_NNP (_( Groton_NNP ,_,
          Connecticut_NNP ,_, United_NNP States_NNPS )_) ,_, and_CC simvastatin_NN was_VBD obtained_VBN from_IN LKT_NNP Labs_NNPS (_( St_NNP ._. Paul_NNP ,_,
          Minnesota_NNP ,_, United_NNP States_NNPS )_) ._. N_NNP 2_CD supplement_NN was_VBD obtained_VBN from_IN Gibco_NNP (_( Carlsbad_NNP ,_, California_NNP ,_,
          United_NNP States_NNPS )_) ._. Sulfo-_NNP NHS-LC-Biotin_NNP was_VBD purchased_VBN from_IN Pierce_NNP (_( Rockford_NNP ,_, Illinois_NNP ,_, United_NNP
          States_NNPS )_) ._. CA_NNP and_CC DN_NNP Myc-tagged_NNP ROCK_NNP 1_CD vectors_NNS were_VBD generated_VBN as_RB previously_RB described_VBD
          [_NN 30_CD ,_, 31_CD ]_NN and_CC were_VBD generous_JJ gifts_NNS from_IN Liqun_NNP Luo_NNP (_( Stanford_NNP University_NNP )_) ._. Fugene_NNP 6_CD was_VBD
          purchased_VBN from_IN Roche_NNP (_( Basel_NNP ,_, Switzerland_NNP )_) ._. Farnesyl_NNP transferase_NN inhibitor_NN 1_CD (_( FTI-_NNP 1_LS )_) was_VBD
          obtained_VBN from_IN Biomol_NNP (_( Plymouth_NNP Meeting_VBG ,_, Pennsylvania_NNP ,_, United_NNP States_NNPS )_) ._. Tumor_NNP necrosis_NNS
          factor_NN α_NN (_( TNFα_NNP )_) protease_NN inhibitor_NN 2_CD and_CC Y-_NNP 27632_CD were_VBD purchased_VBN from_IN Calbiochem_NNP (_( San_NNP
          Diego_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) ._. Protein_NNP concentration_NN assay_NN kit_NN was_VBD purchased_VBN from_IN
          Biorad_NNP (_( Hercules_NNP ,_, California_NNP ,_, United_NNP States_NNPS )_) ._. LIVE_NNP /_NN DEAD_NNP Viability_NNP /_NN Cytotoxicity_NNP Assay_NNP Kits_NNP
          and_CC Amplex_NNP Red_NNP Cholesterol_NNP Assay_NNP Kits_NNP were_VBD purchased_VBN from_IN Molecular_NNP Probes_NNP (_( Eugene_NNP ,_,
          Oregon_NNP ,_, United_NNP States_NNPS )_) ._.
        
        
          Culture_NNP Methods_NNP and_CC Sample_NNP Preparation_NNP
          N_NNP 2_CD a_DT mouse_NN neuroblastoma_NN cells_NNS stably_RB transfected_JJ with_IN the_DT Swedish_JJ mutant_JJ form_NN of_IN APP_NNP
          (_( SweAPP_NNP N_NNP 2_CD a_DT cells_NNS ;_: APP_NNP 695_CD ,_, 595_CD –_NN 596_CD KM_NNP /_NN NL_NNP )_) (_( gift_NN from_IN G_NNP ._. Thinakaran_NNP and_CC S_NNP ._. Sisodia_NNP ,_,
          University_NNP of_IN Chicago_NNP ,_, Chicago_NNP ,_, Illinois_NNP ,_, United_NNP States_NNPS )_) were_VBD maintained_VBN in_IN DMEM_NNP ,_, 10_CD %_NN
          FBS_NNP ,_, and_CC 200_CD μg_NN /_NN ml_NN G_NNP 418_CD in_IN the_DT presence_NN of_IN penicillin_NN and_CC streptomycin_NN [_NN 32_CD ]_NN ._. For_IN the_DT 24_CD h_NN
          prior_RB to_TO pharmacological_JJ treatments_NNS ,_, the_DT culture_NN media_NNS were_VBD changed_VBN to_TO N_NNP 2_CD -_: supplemented_JJ
          lipid-free_JJ medium_NN ._. In_IN some_DT studies_NNS ,_, cells_NNS were_VBD transfected_JJ in_IN N_NNP 2_CD -_: supplemented_JJ FBS-free_NNP
          medium_NN 48_CD h_NN before_IN pharmacological_JJ treatments_NNS ._. Transfections_NNP were_VBD carried_VBN out_IN using_VBG the_DT
          Fugene_NNP reagent_NN ,_, according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._. All_DT treatments_NNS were_VBD
          performed_VBN in_IN the_DT presence_NN of_IN 1_CD μM_NN mevalonic_JJ acid_NN ,_, unless_IN otherwise_RB specified_VBN ._.
          Cells_NNP were_VBD lysed_JJ in_IN 1_CD %_NN Triton-_NNP X_NNP /_NN PBS_NNP buffer_NN containing_VBG 1_CD X_NNP complete_JJ proteinase_NN
          inhibitor_NN cocktail_NN (_( Roche_NNP )_) ,_, sonicated_JJ twice_RB for_IN 30_CD s_VBZ ,_, and_CC centrifuged_JJ at_IN 5_CD ,_, 000_CD
          g_SYM for_IN 5_CD min_NN ._. Protein_NNP concentration_NN in_IN the_DT supernatant_NN was_VBD determined_VBN
          using_VBG the_DT Biorad_NNP Protein_NNP Assay_NNP kit_NN ,_, following_VBG the_DT manufacturer_NN 's_POS instructions_NNS ._. For_IN the_DT
          detection_NN of_IN holoAPP_NN and_CC sAPP_NN
          α_NN ,_, samples_NNS were_VBD separated_JJ in_IN 7_CD ._. 5_CD %_NN polyacrylamide_NN gels_NNS ,_, transferred_VBN to_TO
          nitrocellulose_NN ,_, and_CC the_DT proteins_NNS detected_VBD with_IN either_DT 369_CD (_( 1_CD :_: 3_CD ,_, 000_CD for_IN holoAPP_NN and_CC
          C-_NNP terminal_NN fragments_NNS )_) or_CC 6_CD E_NNP 10_CD (_( 1_CD :_: 1_CD ,_, 000_CD for_IN holoAPP_NN or_CC sAPP_NN
          α_NN )_) ,_, followed_VBN by_IN incubation_NN of_IN the_DT transfers_NNS with_IN appropriate_JJ
          secondary_JJ anti-rabbit_JJ or_CC anti-mouse_JJ antibodies_NNS ._. For_IN the_DT detection_NN of_IN transfected_JJ ROCK_NNP 1_CD
          proteins_NNS ,_, samples_NNS were_VBD immunoprecipitated_JJ with_IN 2_CD μg_NN of_IN anti-_NN Myc_NNP antibody_NN ,_, separated_JJ in_IN 5_CD %_NN
          polyacrylamide_NN gels_NNS ,_, transferred_VBN ,_, and_CC the_DT proteins_NNS detected_VBD with_IN anti-_NN ROCK_NNP 1_CD antibody_NN
          (_( 1_CD :_: 1_CD ,_, 000_CD dilution_NN )_) ._.
        
        
          Cell-_NNP Surface_NNP Biotinylation_NNP
          Cells_NNP were_VBD plated_JJ in_IN a_DT 100_CD -_: mm_NN dish_NN at_IN a_DT concentration_NN of_IN 5_CD ×_NN 10_CD
          6_CD cells_NNS /_NN dish_NN ._. After_IN treatment_NN ,_, media_NNS were_VBD harvested_VBN ,_, and_CC sAPP_NN
          α_NN levels_NNS were_VBD evaluated_VBN by_IN immunoblotting_VBG as_IN described_VBN above_IN ._. Cells_NNP
          were_VBD washed_VBN twice_RB in_IN PBS_NNP and_CC then_RB incubated_JJ with_IN Sulfo-_NNP NHS-LC-Biotin_NNP for_IN 30_CD min_NN at_IN 4_CD 
          o_NN C_NNP ._. Biotinylation_NNP reactions_NNS were_VBD terminated_VBN by_IN one_CD wash_VB in_IN Tris_NNP
          followed_VBN by_IN two_CD washes_NNS in_IN PBS_NNP ._. Cells_NNP were_VBD lysed_JJ in_IN 1_CD %_NN Triton-_NNP X_NNP /_NN PBS_NNP buffer_NN containing_VBG
          protease_NN inhibitor_NN cocktail_NN as_IN indicated_VBN above_IN ._. Lysates_NNP were_VBD immunoprecipitated_JJ with_IN 3_CD μl_NN
          of_IN whole_JJ 369_CD antibody_NN serum_NN and_CC 30_CD μl_NN of_IN protein_NN A_DT beads_NNS ._. After_IN washing_VBG twice_RB with_IN 1_CD %_NN
          Triton_NNP /_NN PBS_NNP ,_, and_CC then_RB twice_RB with_IN PBS_NNP ,_, samples_NNS were_VBD boiled_VBD in_IN sample_NN buffer_NN for_IN 3_CD min_NN ,_,
          separated_JJ in_IN a_DT 7_CD ._. 5_CD %_NN polyacrylamide_NN gel_NN ,_, and_CC transferred_VBD to_TO nitrocellulose_NN ._. The_DT
          biotinylated_JJ proteins_NNS were_VBD detected_VBN using_VBG streptavidin_NN HRP_NNP polymer_NN (_( 1_CD :_: 10_CD ,_, 000_CD
          dilution_NN )_) ._.
        
        
          Viability_NNP /_NN Cytotoxicity_NNP Assays_NNP
          Cells_NNP were_VBD plated_JJ in_IN an_DT eight-well_JJ slide_NN at_IN a_DT concentration_NN of_IN 1_CD ×_NN 10_CD
          4_CD cells_NNS /_NN well_RB ._. After_IN treatments_NNS as_IN indicated_VBN ,_, LIVE_NNP /_NN DEAD_NNP assays_NNS were_VBD
          performed_VBN following_VBG the_DT manufacturer_NN 's_POS instructions_NNS (_( Molecular_NNP Probes_NNP )_) ._.
        
        
          Cholesterol_NNP Assays_NNP
          Cholesterol_NNP levels_NNS in_IN cell_NN lysates_NNS were_VBD measured_VBN using_VBG Amplex_NNP Red_NNP following_VBG the_DT
          manufacturer_NN 's_POS instructions_NNS (_( Molecular_NNP Probes_NNP )_) ._. We_PRP have_VBP previously_RB demonstrated_VBN that_IN
          standard_JJ doses_NNS of_IN either_DT simvastatin_NN or_CC atorvastatin_NN reduce_VB cholesterol_NN levels_NNS in_IN N_NNP 2_CD a_DT
          cells_NNS by_IN 65_CD %_NN –_NN 67_CD %_NN [_NN 16_CD ]_NN ._.
        
        
          Quantification_NNP and_CC Statistical_NNP Analysis_NNP
          Quantification_NNP of_IN protein_NN bands_NNS was_VBD performed_VBN using_VBG the_DT UVP_NNP Bioimaging_NNP System_NNP ,_, and_CC
          statistical_JJ analysis_NN was_VBD performed_VBN on_IN paired_VBN observations_NNS using_VBG the_DT Student_NNP 's_POS 
          t_NN test_NN ._.
        
      
      
        Results_NNS
        
          Atorvastatin_NNP Activates_NNP sAPPα_NN Shedding_NNP at_IN a_DT Subcellular_NNP Site_NNP Upstream_NNP of_IN Endocytosis_NNP
          from_IN the_DT Plasma_NNP Membrane_NNP
          We_PRP confirmed_VBD our_PRP$ previous_JJ observation_NN [_NN 16_CD ]_NN that_DT atorvastatin_NN produces_VBZ an_DT increase_NN in_IN
          sAPP_NN
          α_NN shedding_VBG that_WDT is_VBZ dose-dependent_JJ ,_, reaching_VBG a_DT maximum_NN effect_NN at_IN 5_CD μM_NN ._.
          The_DT increase_NN in_IN sAPP_NN
          α_NN shedding_VBG is_VBZ accompanied_VBN by_IN a_DT corresponding_JJ increase_NN in_IN levels_NNS of_IN the_DT
          nonamyloidogenic_JJ APP_NNP α-_NN C-_NNP terminal_NN fragment_NN (_( C_NNP 83_CD ;_: data_NNS not_RB shown_VBN )_) ._.
          In_IN order_NN to_TO refine_VB our_PRP$ localization_NN of_IN the_DT subcellular_NN target_NN of_IN statin_NN action_NN ,_, we_PRP
          evaluated_VBD the_DT steady-state_JJ levels_NNS of_IN cell-surface_JJ APP_NNP (_( csAPP_NN )_) in_IN the_DT absence_NN or_CC presence_NN
          of_IN statins_NNS ._. After_IN drug_NN treatments_NNS ,_, cells_NNS were_VBD subjected_VBN to_TO the_DT surface_NN biotinylation_NN
          protocol_NN ._. Cells_NNP and_CC media_NNS were_VBD harvested_VBN ,_, and_CC levels_NNS of_IN sAPP_NN
          α_NN ,_, holoAPP_NN ,_, and_CC csAPP_NN were_VBD measured_VBN ._. Treatment_NNP with_IN atorvastatin_NN
          increased_VBN csAPP_NN by_IN approximately_RB 1_CD ._. 6_CD -_: fold_VB ,_, similar_JJ to_TO the_DT effect_NN of_IN the_DT drug_NN on_IN holoAPP_NN
          (_( Figure_NN 1_LS )_) ,_, while_IN sAPP_NN
          α_NN shedding_VBG was_VBD increased_VBN by_IN approximately_RB 7_CD -_: fold_VB (_(
          p_NN <_NN 0_CD ._. 05_CD )_) ._. Since_IN csAPP_NN levels_NNS were_VBD only_RB slightly_RB raised_VBD in_IN the_DT same_JJ
          statin-treated_JJ cells_NNS in_IN which_WDT sAPP_NN
          α_NN shedding_VBG was_VBD dramatically_RB increased_VBN ,_, we_PRP interpret_VBP this_DT disparity_NN to_TO
          indicate_VB that_IN the_DT effector_NN of_IN statin-stimulated_JJ shedding_NN is_VBZ probably_RB intrinsic_JJ to_TO the_DT
          plasma_NN membrane_NN ._. In_IN other_JJ studies_NNS ,_, the_DT plasma_NN membrane_NN has_VBZ been_VBN proposed_VBN to_TO be_VB ,_, or_CC to_TO
          contain_VB ,_, the_DT statin_NN target_NN ._. For_IN example_NN ,_, statins_NNS have_VBP been_VBN proposed_VBN to_TO cause_VB
          co-localization_JJ of_IN α-secretase_JJ and_CC APP_NNP within_IN lipid_NN rafts_NNS [_NN 15_CD ,_, 33_CD ]_NN ;_: statins_NNS might_MD also_RB
          induce_VB modification_NN of_IN the_DT structure_NN and_CC activity_NN of_IN a_DT protein_NN in_IN the_DT plasma_NN membrane_NN
          α-secretase_JJ complex_NN ,_, perhaps_RB in_IN an_DT action_NN similar_JJ to_TO how_WRB statins_NNS bind_NN and_CC “ lock_VB”
          cell-surface_JJ integrins_NNS [_NN 34_CD ]_NN ._.
          A_DT pulse-chase_JJ protocol_NN was_VBD also_RB used_VBN to_TO study_VB post-transcriptional_JJ regulation_NN of_IN APP_NNP
          metabolsm_NN by_IN statins_NNS (_( data_NNS not_RB shown_VBN )_) ._. This_DT protocol_NN avoids_VBZ any_DT confound_NN that_WDT might_MD arise_VB
          because_IN of_IN altered_VBN APP_NNP transcription_NN ._. Pulse-chase_NNP studies_NNS were_VBD performed_VBN using_VBG a_DT 10_CD -_: min_NN
          pulse_NN with_IN [_NN
          35_CD S_NNP ]_NN methionine_NN followed_VBN by_IN various_JJ chase_NN times_NNS from_IN 0_CD to_TO 120_CD min_NN ._.
          Typical_JJ maturation_NN and_CC half-life_NN of_IN mature_VBP cellular_JJ holoAPP_NN were_VBD observed_VBN ,_, as_IN was_VBD
          subsequent_JJ release_NN of_IN sAPP_NN
          α_NN [_NN 5_CD ,_, 29_CD ]_NN ._. In_IN the_DT presence_NN of_IN either_DT atorvastatin_NN or_CC simvastatin_NN ,_, the_DT
          time_NN course_NN of_IN maturation_NN and_CC release_NN perfectly_RB paralleled_JJ that_WDT observed_VBD in_IN the_DT absence_NN
          of_IN either_DT drug_NN ,_, except_IN that_IN the_DT fractional_JJ content_NN of_IN cellular_JJ mature_VBP holoAPP_NN was_VBD
          approximately_RB 2_CD -_: fold_VB greater_JJR in_IN the_DT presence_NN of_IN drug_NN (_( i_NNP ._. e_SYM ._. ,_, at_IN 15_CD or_CC 75_CD min_NN chase_NN ,_, mature_VBP
          APP_NNP in_IN the_DT presence_NN of_IN statin_NN was_VBD approximately_RB 310_CD %_NN of_IN the_DT level_NN of_IN immature_NN APP_NNP at_IN 
          t_NN =_SYM 0_CD versus_CC a_DT control_NN [_NN vehicle_NN treatment_NN ]_NN of_IN 150_CD %_NN of_IN the_DT level_NN of_IN
          immature_NN APP_NNP at_IN 
          t_NN =_SYM 0_CD ;_: also_RB ,_, at_IN 
          t_NN =_SYM 30_CD min_NN ,_, the_DT relative_JJ percent_NN values_NNS for_IN drug_NN versus_CC vehicle_NN were_VBD
          380_CD %_NN and_CC 200_CD %_NN ,_, respectively_RB )_) ._. Fold_NNP increases_NNS in_IN released_VBN sAPP_NN
          α_NN in_IN the_DT same_JJ experiments_NNS were_VBD approximately_RB 3_CD -_: to_TO 4_CD -_: fold_VB (_( 2_CD ._. 0_CD
          arbitrary_JJ units_NNS versus_CC 5_CD ._. 5_CD –_NN 8_CD ._. 0_CD arbitrary_JJ units_NNS at_IN 120_CD min_NN for_IN atorvastatin_NN and_CC
          simvastatin_NN ,_, respectively_RB )_) ._. Secretory_NNP maturation_NN toxicity_NN is_VBZ one_CD possible_JJ mechanism_NN for_IN
          elevated_VBD levels_NNS of_IN intracellular_NN mature_VBP holoAPP_NN and_CC causes_NNS retarded_JJ conversion_NN of_IN mature_VBP
          holoAPP_NN to_TO sAPP_NN
          α_NN ._. This_DT pattern_NN was_VBD not_RB observed_VBN following_VBG statin_NN treatment_NN ,_,
          excluding_VBG maturation_NN toxicity_NN as_IN a_DT mechanism_NN underlying_VBG the_DT altered_VBN levels_NNS of_IN mature_VBP
          cellular_JJ holoAPP_NN ._.
          Instead_RB ,_, the_DT pattern_NN that_IN we_PRP observed_VBD raises_VBZ the_DT possibility_NN that_IN statins_NNS ,_, presumably_RB
          via_IN isoprenoids_NNS (_( given_VBN the_DT reversibility_NN with_IN mevalonate_NN )_) ,_, as_IN discussed_VBN in_IN the_DT next_JJ
          section_NN ,_, may_MD alter_VB sorting_VBG of_IN cellular_JJ holoAPP_NN ,_, diverting_VBG holoproteins_NNS away_RB from_IN terminal_NN
          degradation_NN in_IN the_DT endosomal_NN /_NN lysosomal_NN pathway_NN and_CC into_IN the_DT constitutive_JJ secretory_NN
          pathway_NN that_WDT generates_VBZ sAPP_NN
          α_NN ._. However_RB ,_, the_DT fold_VB effect_NN on_IN reduced_VBN intracellular_NN turnover_NN in_IN the_DT
          endosomal_NN /_NN lysosomal_NN pathway_NN (_( or_CC sorting_VBG out_IN of_IN the_DT endosomal_NN /_NN lysosomal_NN pathway_NN and_CC into_IN
          the_DT constitutive_JJ secretory_NN /_NN shedding_VBG pathway_NN )_) is_VBZ apparently_RB insufficient_JJ to_TO explain_VB the_DT
          fold_VB effect_NN on_IN sAPP_NN
          α_NN generation_NN (_( 2_CD -_: fold_VB for_IN the_DT former_NN ,_, vs_NNS 3_CD -_: to_TO 4_CD -_: fold_VB for_IN the_DT latter_JJ )_) ,_,
          indicating_VBG a_DT contribution_NN from_IN a_DT downstream_JJ site_NN in_IN the_DT processing_NN pathway_NN ._. When_WRB these_DT
          results_NNS are_VBP taken_VBN together_RB with_IN independent_JJ work_NN on_IN regulated_VBN shedding_NN of_IN transforming_VBG
          growth_NN factor_NN α_NN (_( TGFα_NNP )_) [_NN 35_CD ,_, 36_CD ]_NN ,_, a_DT parsimonious_JJ explanation_NN is_VBZ that_IN an_DT important_JJ target_NN
          for_IN activation_NN of_IN ectodomain_NN shedding_NN is_VBZ probably_RB located_VBN at_IN the_DT plasma_NN membrane_NN or_CC
          downstream_JJ of_IN APP_NNP residence_NN at_IN the_DT plasma_NN membrane_NN ._.
          The_DT identification_NN of_IN the_DT regulatory_JJ components_NNS of_IN the_DT ectodomain_NN shedding_VBG machinery_NN
          have_VBP been_VBN long-sought_JJ in_IN other_JJ studies_NNS employing_VBG phorbol_NN esters_NNS to_TO stimulate_VB shedding_NN of_IN
          sAPP_NN
          α_NN or_CC TGFα_NNP [_NN 4_CD ,_, 35_CD ,_, 36_CD ,_, 37_CD ]_NN ._. Munc-_NNP 13_CD has_VBZ recently_RB been_VBN implicated_VBN as_IN a_DT
          phorbol_NN target_NN in_IN regulated_VBN shedding_VBG [_NN 38_CD ]_NN ._. In_IN our_PRP$ opinion_NN ,_, this_DT molecule_NN is_VBZ rather_RB
          unlikely_JJ to_TO play_VB a_DT major_JJ role_NN in_IN shedding_VBG regulation_NN ,_, given_VBN the_DT specificity_NN of_IN Munc-_NNP 13_CD
          effects_NNS for_IN phorbols_NNS and_CC the_DT generalization_NN of_IN the_DT regulated_VBN shedding_VBG phenomenon_NN to_TO
          include_VB activation_NN by_IN protein_NN phosphatase_NN inhibitors_NNS and_CC neurotransmitters_NNS ._. Neither_DT of_IN
          these_DT would_MD be_VB predicted_VBN to_TO act_VB via_IN the_DT phorbol-binding_JJ C_NNP 1_CD domain_NN of_IN Munc-_NNP 13_CD ._.
          Sisodia_NNP and_CC colleagues_NNS [_NN 39_CD ]_NN demonstrated_VBN that_DT arrest_NN of_IN APP_NNP endocytosis_NNS from_IN the_DT
          plasma_NN membrane_NN by_IN deletion_NN of_IN its_PRP$ 
          NPXY_NNP clathrin-coated_JJ vesicle_NN targeting_VBG sequence_NN [_NN 40_CD ,_, 41_CD ]_NN can_MD
          dramatically_RB stimulate_VB sAPP_NN
          α_NN shedding_NN ,_, presumably_RB by_IN extending_VBG the_DT half-life_NN of_IN co-localized_JJ
          α-secretase_JJ and_CC APP_NNP on_IN the_DT plasma_NN membrane_NN ._. In_IN order_NN to_TO exclude_VB the_DT possible_JJ contribution_NN
          of_IN altered_VBN endocytosis_NNS to_TO statin-stimulated_JJ shedding_NN ,_, we_PRP evaluated_VBD the_DT effect_NN of_IN
          phenylarsine_NN oxide_NN (_( PO_NNP )_) ,_, an_DT inhibitor_NN of_IN endocytosis_NNS ,_, on_IN statin-stimulated_JJ shedding_NN
          (_( Figure_NN 2_LS )_) ._. Treatment_NNP with_IN either_DT atorvastatin_NN ,_, simvastatin_NN ,_, or_CC PO_NNP alone_RB increased_VBD sAPP_NN
          α_NN shedding_NN ,_, as_IN expected_VBN ._. Co-treatment_NNP of_IN cells_NNS with_IN PO_NNP plus_CC either_CC
          atorvastatin_NN or_CC simvastatin_NN caused_VBD stimulation_NN of_IN sAPP_NN
          α_NN shedding_VBG to_TO levels_NNS greater_JJR than_IN the_DT maximal_NN levels_NNS of_IN shedding_VBG
          achievable_JJ with_IN inhibition_NN of_IN endocytosis_NNS using_VBG PO_NNP alone_RB or_CC with_IN maximal_NN doses_NNS of_IN either_DT
          statin_NN alone_RB (_(
          p_NN <_NN 0_CD ._. 05_CD )_) ._. The_DT additivity_NN of_IN statin-_NN and_CC PO-stimulated_NNP shedding_VBG is_VBZ
          consistent_JJ with_IN the_DT hypothesis_NNS that_IN statins_NNS act_VBP at_IN or_CC near_IN the_DT plasma_NN membrane_NN ,_, prior_RB to_TO
          internalization_NN of_IN csAPP_NN ._. Under_IN all_DT circumstances_NNS ,_, stimulated_VBN sAPP_NN
          α_NN shedding_VBG was_VBD completely_RB blocked_VBN using_VBG TNFα_NNP protease_NN inhibitor_NN 2_CD ,_, a_DT
          standard_JJ α-secretase_JJ /_NN metalloproteinase_NN inhibitor_NN (_( Figure_NN 2_LS )_) ._. We_PRP interpret_VBP this_DT as_IN an_DT
          indication_NN that_IN the_DT statin-induced_JJ α-cleavage_JJ of_IN APP_NNP is_VBZ probably_RB mediated_JJ by_IN one_CD of_IN the_DT
          molecules_NNS usually_RB associated_VBN with_IN the_DT phenomenon_NN ,_, i_NNP ._. e_SYM ._. ,_, ADAM-_NNP 10_CD or_CC ADAM-_NNP 17_CD [_NN 16_CD ]_NN ._.
        
        
          Compounds_NNP that_IN Modulate_NNP Isoprenoid_NNP Levels_NNP Activate_NNP sAPPα_NN Shedding_NNP
          As_IN discussed_VBN above_IN ,_, there_EX is_VBZ an_DT established_VBN relationship_NN between_IN statins_NNS and_CC
          isoprenoid-modulated_JJ protein_NN phosphorylation_NN ._. We_PRP therefore_RB tested_VBD the_DT effects_NNS of_IN FTI-_NNP 1_CD on_IN
          statin-stimulated_JJ sAPP_NN
          α_NN shedding_NN ._. FTI-_NNP 1_CD increased_VBD the_DT shedding_NN of_IN sAPP_NN
          α_NN ,_, but_CC the_DT combination_NN of_IN a_DT statin_NN plus_CC FTI-_NNP 1_CD increased_VBN sAPP_NN
          α_NN shedding_VBG to_TO levels_NNS greater_JJR than_IN those_DT achievable_JJ by_IN using_VBG either_DT
          compound_NN alone_RB (_( Figure_NN 3_CD ;_: 
          p_NN <_NN 0_CD ._. 05_CD )_) ._. In_IN the_DT same_JJ experiment_NN ,_, levels_NNS of_IN holoAPP_NN were_VBD modestly_RB
          increased_VBN but_CC ,_, again_RB ,_, to_TO an_DT extent_NN insufficient_JJ to_TO account_VB for_IN the_DT increase_NN in_IN shed_VB sAPP_NN
          α_NN (_( Figure_NN 3_LS )_) ._.
          To_TO test_VB whether_IN statin-activated_JJ shedding_NN might_MD be_VB attributable_JJ to_TO a_DT metabolite_NN
          downstream_JJ of_IN HMGCoA_NNP reductase_NN ,_, cells_NNS were_VBD treated_VBN with_IN 1_CD μM_NN simvastatin_NN ,_, 5_CD μM_NN FTI-_NNP 1_CD ,_, and_CC
          a_DT series_NN of_IN concentrations_NNS of_IN mevalonic_JJ acid_NN ._. Since_IN FTI-_NNP 1_CD acts_NNS downstream_JJ of_IN HMGCoA_NNP
          reductase_NN ,_, the_DT stimulatory_NN effect_NN of_IN FTI-_NNP 1_CD on_IN sAPP_NN
          α_NN shedding_VBG would_MD not_RB be_VB predicted_VBN to_TO be_VB modified_VBN by_IN mevalonate_NN
          supplementation_NN ._. Low_NNP doses_NNS (_( <_NN 1_CD μM_NN )_) of_IN mevalonic_JJ acid_NN did_VBD not_RB affect_VB statin-induced_JJ
          sAPP_NN
          α_NN shedding_NN ,_, but_CC complete_JJ inhibition_NN of_IN statin-activated_JJ sAPP_NN
          α_NN shedding_VBG was_VBD achieved_VBN with_IN higher_JJR doses_NNS of_IN mevalonic_JJ acid_NN (_( 100_CD μM_NN )_) ._.
          As_IN predicted_VBD ,_, the_DT shedding_VBG observed_VBN following_VBG treatment_NN with_IN FTI-_NNP 1_CD was_VBD not_RB inhibited_VBD by_IN
          any_DT of_IN the_DT concentrations_NNS of_IN mevalonic_JJ acid_NN tested_VBN (_( Figure_NN 4_LS )_) ._. These_DT data_NNS are_VBP consistent_JJ
          with_IN a_DT role_NN for_IN isoprenoids_NNS in_IN statin_NN control_NN of_IN APP_NNP metabolism_NN in_IN cultured_JJ cells_NNS ._.
        
        
          Expression_NNP of_IN ROCK-Related_NNP Molecules_NNP Modulates_NNP sAPPα_NN Shedding_NNP in_IN a_DT Bidirectional_NNP
          Manner_NNP
          Since_IN many_JJ isoprenoid-mediated_JJ Rho_NNP effects_NNS converge_NN on_IN ROCKs_NNP ,_, we_PRP next_JJ transfected_JJ N_NNP 2_CD a_DT
          cells_NNS with_IN cDNAs_NNS encoding_VBG either_CC green_JJ fluorescent_NN protein_NN (_( GFP_NNP )_) (_( control_NN )_) ,_, CA_NNP ROCK_NNP 1_CD ,_, or_CC
          DN_NNP ROCK_NNP 1_CD (_( Figure_NN 5_LS )_) ._. Simvastatin_NNP caused_VBD a_DT typical_JJ activation_NN of_IN sAPP_NN
          α_NN shedding_VBG from_IN GFP-transfected_NNP cells_NNS ._. When_WRB CA_NNP ROCK_NNP 1_CD was_VBD introduced_VBN ,_,
          however_RB ,_, shedding_NN of_IN sAPP_NN
          α_NN from_IN both_DT untreated_JJ and_CC simvastatin-treated_JJ cells_NNS was_VBD diminished_VBN
          (_( Figure_NN 5_CD ;_: 
          p_NN <_NN 0_CD ._. 05_CD versus_CC GFP_NNP control_NN )_) ._. Conversely_RB ,_, DN_NNP ROCK_NNP 1_CD alone_RB activated_VBN
          shedding_NN of_IN sAPP_NN
          α_NN ._. Cellular_NNP levels_NNS of_IN holoAPP_NN were_VBD not_RB affected_VBN by_IN transfection_NN
          (_( Figure_NN 5_CD ;_: 
          p_NN <_NN 0_CD ._. 05_CD versus_CC GFP_NNP control_NN )_) ._. In_IN studies_NNS aimed_VBN at_IN independent_JJ
          confirmation_NN of_IN the_DT involvement_NN of_IN ROCK_NNP activation_NN in_IN sAPP_NN
          α_NN shedding_NN ,_, we_PRP treated_VBD SweAPP_NNP N_NNP 2_CD a_DT cells_NNS with_IN arachidonic_JJ acid_NN ,_, an_DT
          activator_NN of_IN ROCK_NNP ._. As_IN shown_VBN in_IN Figure_NN 6_CD ,_, arachidonic_JJ acid_NN reduced_VBD the_DT shedding_NN of_IN sAPP_NN
          α_NN without_IN altering_VBG levels_NNS of_IN holoAPP_NN ._. Based_VBN on_IN this_DT series_NN of_IN results_NNS ,_,
          we_PRP concluded_VBD that_IN both_DT basal_NN and_CC activated_VBN sAPP_NN
          α_NN shedding_VBG from_IN cultured_JJ cells_NNS are_VBP controlled_VBN by_IN ROCK_NNP activity_NN ._.
          In_IN some_DT experiments_NNS ,_, cells_NNS were_VBD treated_VBN with_IN Y-_NNP 27632_CD (_( 10_CD nM_NN to_TO 50_CD μM_NN )_) ,_, a_DT compound_NN that_WDT
          can_MD inhibit_VB ROCKs_NNP ._. Y-_NNP 27632_CD showed_VBD no_DT effect_NN on_IN basal_NN sAPP_NN
          α_NN release_NN and_CC blocked_VBN statin-activated_JJ sAPP_NN
          α_NN shedding_VBG (_( data_NNS not_RB shown_VBN )_) ._. This_DT result_NN was_VBD unexpected_JJ in_IN light_NN of_IN
          the_DT effects_NNS of_IN DN_NNP ROCK_NNP 1_CD ._. Given_VBN the_DT internally_RB consistent_JJ actions_NNS of_IN DN_NNP ROCK_NNP 1_CD and_CC CA_NNP
          ROCK_NNP 1_CD ,_, as_RB well_RB as_IN the_DT results_NNS employing_VBG either_CC FTI-_NNP 1_CD or_CC arachidonate_NN ,_, we_PRP concluded_VBD that_IN
          the_DT Y-_NNP 27632_CD result_NN might_MD be_VB due_JJ to_TO inhibition_NN by_IN Y-_NNP 27632_CD of_IN protein_NN kinases_NNS other_JJ than_IN
          ROCK_NNP 1_CD [_NN 23_CD ]_NN ._. The_DT possibility_NN was_VBD also_RB considered_VBN that_DT cytotoxicity_NN of_IN Y-_NNP 27632_CD for_IN the_DT
          central_JJ vacuolar_NN pathway_NN might_MD explain_VB the_DT disparity_NN between_IN the_DT effects_NNS of_IN DN_NNP ROCK_NNP 1_CD and_CC
          those_DT of_IN Y-_NNP 27632_CD ,_, but_CC neither_DT impairment_NN of_IN intracellular_NN APP_NNP maturation_NN nor_CC increased_VBN
          apoptosis_NNS as_IN measured_VBN by_IN LIVE_NNP /_NN DEAD_NNP assay_NN were_VBD apparent_JJ following_NN Y-_NNP 27632_CD treatment_NN (_( data_NNS
          not_RB shown_VBN )_) ._. Ultimately_RB ,_, we_PRP were_VBD unable_JJ to_TO document_VB any_DT explanation_NN for_IN the_DT disparate_JJ
          results_NNS of_IN Y-_NNP 27632_CD and_CC DN_NNP ROCK_NNP 1_CD ._.
        
      
      
        Discussion_NNP
        The_DT isoprenoid_NN pathway_NN involves_VBZ lipid_NN modification_NN of_IN various_JJ members_NNS of_IN the_DT Rho_NNP family_NN
        of_IN small_JJ GTPases_NNP by_IN the_DT addition_NN of_IN either_DT farnesyl_NN or_CC geranylgeranyl_NN moieties_NNS [_NN 20_CD ,_, 42_CD ]_NN ._.
        Isoprenylation_NNP serves_VBZ to_TO target_VB the_DT GTPases_NNP to_TO the_DT proper_JJ organelle_NN membrane_NN ,_, where_WRB their_PRP$
        actions_NNS often_RB relate_VBP to_TO cytoskeletal_NN dynamics_NNS and_CC /_NN or_CC vesicle_NN trafficking_NN [_NN 20_CD ,_, 42_CD ]_NN ._. ROCKs_NNP are_VBP
        important_JJ downstream_JJ targets_NNS of_IN Rho_NNP (_( Figure_NN 7_CD )_) ,_, catalyzing_VBG the_DT phosphorylation_NN of_IN effector_NN
        phosphoprotein_NN substrates_NNS [_NN 23_CD ]_NN ._. The_DT foregoing_VBG data_NN indicate_VBP that_IN statin-induced_JJ activation_NN
        of_IN APP_NNP shedding_VBG in_IN cultured_JJ cells_NNS involves_VBZ the_DT Rho_NNP /_NN ROCK_NNP pathway_NN ._. More_RBR specifically_RB ,_, the_DT
        data_NNS indicate_VBP that_IN ROCK_NNP 1_CD activation_NN blocks_VBZ the_DT effects_NNS of_IN statins_NNS on_IN APP_NNP ectodomain_NN
        shedding_NN ,_, while_IN ROCK_NNP 1_CD blockade_NN alone_RB can_MD mimic_VB the_DT effect_NN of_IN statins_NNS on_IN APP_NNP shedding_VBG ._. By_IN
        extension_NN ,_, these_DT data_NNS predict_VBP that_DT application_NN of_IN statins_NNS to_TO neurons_NNS might_MD directly_RB or_CC
        indirectly_RB inhibit_VB ROCK_NNP 1_CD activity_NN ._. Evaluation_NNP of_IN this_DT possibility_NN will_MD be_VB the_DT subject_NN of_IN
        future_JJ investigation_NN ._.
        The_DT first_JJ evidence_NN that_IN APP_NNP might_MD be_VB a_DT substrate_NN for_IN ectodomain_NN shedding_VBG was_VBD provided_VBN by_IN
        Weidemann_NNP et_CC al_NN ._. [_NN 43_CD ]_NN who_WP identified_VBD sAPP_NN
        α_NN in_IN the_DT cerebrospinal_NN fluid_NN and_CC blood_NN ._. This_DT aspect_NN of_IN APP_NNP metabolism_NN
        bears_VBZ resemblance_NN to_TO the_DT proteolytic_JJ signal_NN transduction_NN pathways_NNS involved_VBN in_IN processing_NN
        pro-_JJ TGFα_NNP [_NN 35_CD ,_, 36_CD ]_NN and_CC Notch_NNP [_NN 44_CD ]_NN ._. In_IN the_DT case_NN of_IN Notch_NNP ,_, the_DT process_NN is_VBZ set_VBN in_IN motion_NN by_IN the_DT
        binding_VBG of_IN a_DT ligand_NN to_TO the_DT Notch_NNP ectodomain_NN ,_, triggering_VBG its_PRP$ release_NN (_( shedding_VBG )_) ._. For_IN APP_NNP ,_,
        intracellular_NN signal_NN transduction_NN appears_VBZ to_TO be_VB more_RBR important_JJ [_NN 2_CD ,_, 29_CD ,_, 45_CD ]_NN ._. In_IN early_JJ studies_NNS ,_,
        the_DT existence_NN of_IN the_DT shed_VB ectodomain_NN of_IN APP_NNP was_VBD used_VBN to_TO deduce_NN the_DT existence_NN of_IN the_DT
        proteolytic_JJ activity_NN designated_VBN α-secretase_JJ ,_, which_WDT has_VBZ the_DT unusual_JJ specificity_NN of_IN cleaving_VBG
        its_PRP$ substrates_NNS at_IN a_DT proscribed_VBN distance_NN from_IN the_DT extracellular_NN leaflet_NN of_IN the_DT plasma_NN
        membrane_NN [_NN 4_CD ,_, 39_CD ]_NN ._. Ultimately_RB ,_, the_DT integral_JJ cell-surface_JJ metalloproteinases_NNS ADAM-_NNP 10_CD and_CC
        ADAM-_NNP 17_CD /_NN TACE_NNP were_VBD found_VBN to_TO underlie_VB α-secretase-type_JJ ectodomain_NN shedding_VBG [_NN 3_CD ,_, 46_CD ]_NN ._.
        Why_WRB is_VBZ APP_NNP a_DT substrate_NN for_IN ectodomain_NN shedding_NN ?_. To_TO answer_VB this_DT question_NN requires_VBZ
        contemplation_NN of_IN the_DT physiological_JJ function_NN of_IN APP_NNP ._. APP_NNP is_VBZ a_DT type_NN 1_CD integral_JJ protein_NN that_WDT
        is_VBZ subjected_VBN to_TO a_DT host_NN of_IN post-translational_JJ processing_NN events_NNS ,_, including_VBG N-_NNP and_CC
        O-_NNP glycosylation_NN ,_, tyrosyl_NN sulfation_NN ,_, phosphorylation_NN ,_, and_CC proteolysis_NNS [_NN 39_CD ,_, 43_CD ,_, 47_CD ,_, 48_CD ]_NN ._. Most_JJS
        (_( 60_CD %_NN –_NN 80_CD %_NN )_) newly_RB synthesized_JJ APP_NNP is_VBZ subjected_VBN to_TO terminal_NN intracellular_NN degradation_NN that_WDT
        generates_VBZ no_DT discrete_JJ fragments_NNS [_NN 5_CD ]_NN ._. A_DT smaller_JJR fraction_NN of_IN APP_NNP molecules_NNS (_( approximately_RB 20_CD %_NN
        in_IN PC_NN 12_CD cells_NNS under_IN basal_NN conditions_NNS [_NN 5_CD ]_NN )_) undergoes_NNS ectodomain_NN shedding_VBG catalyzed_JJ by_IN either_DT
        the_DT α-secretase_JJ (_( nonamyloidogenic_JJ )_) or_CC β-secretase_JJ (_( potentially_RB amyloiodgenic_JJ )_) pathway_NN ._. When_WRB
        PKC_NNP is_VBZ activated_VBN ,_, the_DT stoichiometry_NN of_IN shed_VB sAPP_NN
        α_NN rises_VBZ from_IN 2_CD mol_NN shed_VB per_IN 10_CD mol_NN synthesized_JJ to_TO 4_CD mol_NN shed_VB per_IN mole_NN
        synthesized_JJ ._. Most_JJS of_IN this_DT shedding_VBG is_VBZ catalyzed_JJ by_IN the_DT α-secretase_JJ pathway_NN ,_, but_CC a_DT trace_VB
        amount_NN (_( <_NN 5_CD %_NN [_NN 49_CD ]_NN )_) is_VBZ catalyzed_JJ by_IN β-secretase_JJ /_NN β-site_JJ APP_NNP cleaving_VBG enzyme_NN [_NN 50_CD ]_NN ._. sAPP_NN
        α_NN and_CC sAPP_NN
        β_NN differ_VB by_IN the_DT inclusion_NN in_IN sAPP_NN
        α_NN of_IN the_DT first_JJ 16_CD residues_NNS of_IN Aβ_NNP ._. Unlike_IN sAPP_NN
        α_NN ,_, which_WDT is_VBZ generated_VBN at_IN the_DT plasma_NN membrane_NN ,_, most_JJS sAPP_NN
        β_NN is_VBZ probably_RB generated_VBN by_IN cleavage_NN within_IN the_DT 
        trans_NNS -_: Golgi_NNP network_NN and_CC endocytic_JJ pathway_NN vesicles_NNS ._. HoloAPP_NNP levels_NNS are_VBP
        likely_JJ limiting_VBG at_IN one_CD or_CC more_JJR sorting_VBG steps_NNS in_IN the_DT late_JJ secretory_NN pathway_NN ,_, since_IN activated_VBN
        sAPP_NN
        α_NN shedding_NN is_VBZ apparently_RB accompanied_VBN by_IN diminished_VBN generation_NN of_IN sAPP_NN
        β_NN [_NN 51_CD ]_NN ._.
        What_WP is_VBZ the_DT function_NN of_IN shed_VB sAPP_NN
        α_NN ?_. Again_RB ,_, from_IN other_JJ molecules_NNS ,_, we_PRP know_VBP that_IN shedding_VBG can_MD serve_VB
        important_JJ cellular_JJ functions_NNS by_IN releasing_VBG diffusible_JJ ligands_NNS from_IN their_PRP$ membrane-bound_JJ
        precursors_NNS (_( e_SYM ._. g_SYM ._. ,_, TGFα_NNP and_CC TNFα_NNP )_) or_CC by_IN terminating_VBG intercellular_NN signaling_VBG (_( e_SYM ._. g_SYM ._. ,_, Notch_NNP )_) ._. A_DT
        popular_JJ model_NN holds_VBZ that_DT sAPP_NN
        α_NN may_MD function_VB as_IN a_DT neurotrophic_JJ and_CC /_NN or_CC neuroprotective_JJ factor_NN ,_, and_CC may_MD
        promote_VB neurite_NN outgrowth_NN [_NN 52_CD ]_NN ._. More_RBR recent_JJ evidence_NN suggests_VBZ that_WDT released_VBD APP_NNP derivatives_NNS
        modulate_VBP efficacy_NN of_IN neurotransmission_NN at_IN the_DT synapse_NN [_NN 53_CD ]_NN ._. Targeted_NNP deletion_NN of_IN APP_NNP has_VBZ
        not_RB revealed_VBN a_DT striking_JJ phenotype_NN [_NN 54_CD ]_NN ,_, presumably_RB because_IN of_IN functional_JJ redundancy_NN
        supplied_VBN by_IN APP-like_NNP proteins_NNS [_NN 55_CD ]_NN ._. Mice_NNS with_IN double_JJ and_CC triple_JJ null_NN mutations_NNS in_IN various_JJ
        combinations_NNS of_IN APP_NNP ,_, APP-like_NNP protein_NN 1_CD ,_, and_CC APP-like_NNP protein_NN 2_CD are_VBP now_RB being_VBG created_VBN ,_, in_IN
        search_NN of_IN evidence_NN for_IN a_DT definitive_JJ function_NN for_IN APP_NNP ._.
        Cao_NNP and_CC Sudhof_NNP [_NN 56_CD ]_NN have_VBP recently_RB discovered_VBN that_IN the_DT APP_NNP C-_NNP terminal_NN fragment_NN generated_VBN
        by_IN α-_NN or_CC β-secretase_JJ is_VBZ itself_PRP cleaved_JJ to_TO release_VB Aβ_NNP and_CC an_DT APP_NNP intracellular_NN domain_NN (_( AICD_NNP )_)
        that_IN diffuses_NNS into_IN the_DT nucleus_NN ,_, possibly_RB acting_VBG there_RB as_IN a_DT transcription_NN factor_NN ._. The_DT
        pathway_NN leading_VBG to_TO AICD_NNP must_MD be_VB initiated_VBN by_IN ectodomain_NN shedding_VBG :_: holoAPP_NN cannot_NN directly_RB
        give_VB rise_NN to_TO AICD_NNP ._. Therefore_RB ,_, one_CD important_JJ function_NN for_IN α-_NN and_CC /_NN or_CC β-secretase_JJ processing_NN
        of_IN APP_NNP may_MD be_VB the_DT eventual_JJ generation_NN of_IN AICD_NNP ._. Our_PRP$ results_NNS suggest_VBP that_IN Rho_NNP /_NN ROCK_NNP signaling_VBG
        provides_VBZ modulation_NN of_IN basal_NN and_CC stimulated_VBN α-secretase_JJ activity_NN ._. It_PRP will_MD now_RB be_VB important_JJ
        to_TO dissect_NN pathways_NNS upstream_RB of_IN Rho_NNP /_NN ROCK_NNP signaling_VBG in_IN order_NN to_TO identify_VB the_DT intracellular_NN
        and_CC intercellular_NN events_NNS that_WDT participate_VBP in_IN Rho_NNP /_NN ROCK_NNP regulation_NN of_IN α-secretase_JJ under_IN
        physiological_JJ and_CC pathological_JJ conditions_NNS ._.
        The_DT potential_JJ role_NN of_IN cholesterol_NN in_IN α-secretase-mediated_JJ shedding_NN was_VBD discovered_VBN by_IN
        Bodovitz_NNP and_CC Klein_NNP [_NN 57_CD ]_NN who_WP used_VBD β-cyclodextrin_JJ to_TO lower_JJR cellular_JJ cholesterol_NN ._. Kojro_NNP et_CC al_NN ._.
        [_NN 15_CD ]_NN confirmed_VBD this_DT observation_NN ,_, using_VBG not_RB only_RB β-cyclodextrin_JJ but_CC also_RB lovastatin_NN to_TO lower_JJR
        cellular_JJ cholesterol_NN ._. These_DT investigators_NNS proposed_VBN that_WDT elevated_VBD ADAM-_NNP 10_CD activity_NN and_CC
        protein_NN levels_NNS contributed_VBD to_TO these_DT effects_NNS ._. These_DT basic_JJ observations_NNS dovetailed_JJ with_IN
        emerging_VBG epidemiological_JJ evidence_NN that_DT administration_NN of_IN statins_NNS might_MD lead_VB to_TO a_DT diminished_VBN
        incidence_NN of_IN Alzheimer_NNP disease_NN [_NN 8_CD ,_, 9_CD ,_, 10_CD ,_, 11_CD ]_NN ._. Despite_IN this_DT ,_, however_RB ,_, the_DT association_NN of_IN
        statins_NNS and_CC cholesterol_NN levels_NNS with_IN activated_VBN α-secretase-mediated_JJ shedding_NN of_IN the_DT APP_NNP
        ectodomain_NN was_VBD unexpected_JJ and_CC not_RB readily_RB explicable_JJ by_IN existing_VBG knowledge_NN regarding_VBG
        regulation_NN of_IN α-secretase_JJ activity_NN ._. The_DT best_RBS characterized_VBN regulation_NN of_IN α-secretase_JJ
        processing_NN typically_RB involves_VBZ protein_NN phosphorylation_NN via_IN PKC_NNP [_NN 5_CD ,_, 29_CD ]_NN or_CC ERKs_NNP [_NN 7_CD ]_NN or_CC protein_NN
        dephosphorylation_NN by_IN protein_NN phosphatase_NN 1_CD or_CC 2_CD A_DT [_NN 29_CD ]_NN ._. We_PRP recently_RB excluded_VBD the_DT possibility_NN
        that_IN either_DT PKC_NNP or_CC ERK_NNP plays_VBZ a_DT role_NN in_IN statin-activated_JJ shedding_NN [_NN 16_CD ]_NN ,_, raising_VBG the_DT
        possibility_NN that_IN other_JJ protein_NN phosphorylation_NN signaling_VBG pathways_NNS might_MD link_VB statins_NNS and_CC /_NN or_CC
        cholesterol_NN to_TO α-secretase_JJ activation_NN ._.
        Maillet_NNP et_CC al_NN ._. [_NN 58_CD ]_NN implicated_VBN the_DT Rho_NNP pathway_NN in_IN modulation_NN of_IN α-secretase_JJ activity_NN
        while_IN dissecting_VBG the_DT activated_VBN shedding_VBG process_NN that_WDT accompanies_VBZ serotonergic_JJ signal_NN
        transduction_NN ._. These_DT investigators_NNS discovered_VBN that_IN Rap_NNP 1_CD acts_NNS through_IN Rac_NNP to_TO modulate_VBP
        α-secretase_JJ processing_NN of_IN APP_NNP ._. Soon_RB thereafter_RB ,_, ROCK_NNP 1_CD was_VBD discovered_VBN by_IN Zhou_NNP et_CC al_NN ._. [_NN 28_CD ]_NN to_TO
        modulate_VBP a_DT downstream_JJ processing_NN step_NN in_IN APP_NNP metabolism_NN that_WDT involves_VBZ
        presenilin_NN /_NN γ-secretase-mediated_JJ proteolysis_NNS of_IN APP_NNP C-_NNP terminal_NN fragments_NNS C_NNP 99_CD and_CC C_NNP 83_CD ._. These_DT
        investigators_NNS discovered_VBN that_DT activation_NN of_IN ROCK_NNP 1_CD may_MD account_VB for_IN how_WRB nonsteroidal_NN
        anti-inflammatory_JJ drugs_NNS specify_VB the_DT scissile_NN bond_NN within_IN the_DT APP_NNP transmembrane_NN domain_NN that_WDT
        is_VBZ cleaved_JJ by_IN presenilin_NN /_NN γ-secretase_JJ to_TO generate_VB the_DT C-_NNP terminus_JJ of_IN Aβ_NNP ._. Based_VBN on_IN these_DT
        reports_NNS ,_, we_PRP asked_VBD whether_IN the_DT Rho_NNP /_NN ROCK_NNP pathway_NN might_MD play_VB a_DT role_NN in_IN controlling_VBG shedding_NN of_IN
        sAPP_NN
        α_NN following_VBG statin_NN application_NN ._.
        CA_NNP ROCK_NNP 1_CD and_CC DN_NNP ROCK_NNP 1_CD molecules_NNS yielded_VBD direct_JJ and_CC complementary_JJ evidence_NN that_IN ROCK_NNP 1_CD was_VBD
        indeed_RB a_DT candidate_NN for_IN modulation_NN of_IN statin-activated_JJ α-secretase_JJ action_NN ._. Further_RB ,_, we_PRP were_VBD
        able_JJ to_TO demonstrate_VB that_IN α-secretase_JJ activity_NN could_MD be_VB modulated_JJ by_IN molecules_NNS further_JJ
        upstream_RB in_IN the_DT isoprenoid_NN pathway_NN (_( see_VB Figure_NN 7_CD )_) ._. FTI-_NNP 1_CD ,_, an_DT inhibitor_NN of_IN farnesyl_NN
        transferase_NN also_RB known_VBN as_IN L-_NNP 744_CD ,_, 832_CD [_NN 59_CD ]_NN ,_, mimicked_JJ and_CC potentiated_JJ statin-activated_JJ
        shedding_NN ,_, presumably_RB by_IN blocking_VBG transfer_NN of_IN isoprenoid_NN moieties_NNS to_TO a_DT Rho_NNP protein_NN by_IN
        farnesyl_NN transferase_NN ,_, and_CC thereby_RB decreasing_VBG Rho_NNP activity_NN ._. However_RB ,_, FTI-_NNP 1_CD treatment_NN can_MD
        also_RB increase_VB the_DT level_NN of_IN geranylgeranylated_JJ isoforms_NNS of_IN certain_JJ Rho_NNP proteins_NNS ,_, e_SYM ._. g_SYM ._. ,_, the_DT
        inhibitory_NN geranylgeranylated_JJ RhoB_NNP protein_NN [_NN 60_CD ]_NN ._. In_IN further_JJ support_NN of_IN a_DT role_NN for_IN
        isoprenoids_NNS ,_, we_PRP were_VBD able_JJ to_TO demonstrate_VB that_DT supplementation_NN of_IN cells_NNS with_IN mevalonate_NN
        abolished_VBD statin-activated_JJ shedding_NN (_( see_VB Figure_NN 4_LS )_) ._. Statins_NNP block_VB HMGCoA_NNP reductase_NN
        generation_NN of_IN mevalonate_NN from_IN 3_CD -_: hydroxy-methyl-glutarate_JJ (_( see_VB Figure_NN 7_CD )_) ._. Therefore_RB ,_, the_DT
        addition_NN of_IN mevalonate_NN would_MD be_VB predicted_VBN to_TO antagonize_VB statin_NN action_NN via_IN the_DT isoprenoid_NN
        pathway_NN ,_, by_IN relieving_VBG statin-induced_JJ mevalonate_NN deficiency_NN ._. As_IN predicted_VBN by_IN this_DT model_NN ,_, we_PRP
        observed_VBD that_IN statin-activated_JJ shedding_NN was_VBD abolished_VBN by_IN adding_VBG mevalonate_NN ._. Taken_VBN together_RB ,_,
        these_DT results_NNS suggest_VBP the_DT existence_NN of_IN a_DT reciprocal_JJ relationship_NN between_IN
        isoprenoid-mediated_JJ Rho_NNP /_NN ROCK_NNP signaling_VBG and_CC sAPP_NN
        α_NN shedding_NN ,_, i_NNP ._. e_SYM ._. ,_, activation_NN of_IN ROCK_NNP 1_CD blocks_NNS basal_NN and_CC stimulated_VBN
        shedding_VBG while_IN ROCK_NNP 1_CD inhibition_NN apparently_RB relieves_NNS a_DT tonic_NN negative_JJ influence_NN exerted_VBN on_IN
        shedding_VBG by_IN ROCK_NNP 1_CD activity_NN ._.
        As_IN in_IN PKC-_NNP and_CC ERK-activated_NNP shedding_VBG ,_, the_DT ROCK_NNP 1_CD substrate_NN effector_NN molecule_NN or_CC
        molecules_NNS that_WDT regulate_VB proteolysis_NNS by_IN ADAMs_NNP remain_VBP to_TO be_VB identified_VBN ._. The_DT cytoplasmic_JJ
        domains_NNS of_IN both_DT APP_NNP and_CC ADAM-_NNP 17_CD have_VBP been_VBN evaluated_VBN as_IN candidates_NNS for_IN important_JJ targets_NNS of_IN
        protein_NN phosphorylation_NN during_IN the_DT regulated_VBN shedding_VBG process_NN ,_, but_CC neither_DT “ substrate_NN
        activation_NN” nor_CC “ enzyme_NN activation_NN” appears_VBZ to_TO explain_VB the_DT phenomenon_NN ,_, i_NNP ._. e_SYM ._. ,_,
        phosphorylation_NN of_IN neither_DT APP_NNP nor_CC ADAM-_NNP 17_CD dramatically_RB increases_VBZ the_DT efficiency_NN of_IN
        α-secretion_JJ [_NN 61_CD ,_, 62_CD ]_NN ,_, indicating_VBG that_DT activation_NN is_VBZ more_RBR indirect_JJ ._.
        Our_PRP$ data_NNS using_VBG statins_NNS and_CC PO_NNP localize_NN the_DT mediator_NN of_IN statin-activated_JJ shedding_NN to_TO the_DT
        plasma_NN membrane_NN ,_, upstream_RB of_IN endocytosis_NNS ,_, as_IN appears_VBZ to_TO be_VB the_DT case_NN for_IN PKC-activated_NNP
        shedding_VBG [_NN 36_CD ,_, 63_CD ,_, 64_CD ,_, 65_CD ]_NN ._. Similar_JJ conclusions_NNS were_VBD drawn_VBN by_IN Bosenberg_NNP and_CC colleagues_NNS [_NN 36_CD ]_NN who_WP
        used_VBD streptolysin-porated_JJ cells_NNS and_CC N-_NNP ethylmaleimide_NN to_TO demonstrate_VB that_DT reconstitution_NN of_IN
        activated_VBN shedding_NN of_IN TGFα_NNP from_IN CHO_NNP cells_NNS does_VBZ not_RB require_VB membrane_NN trafficking_NN and_CC
        apparently_RB occurs_VBZ on_IN the_DT plasma_NN membrane_NN ._. These_DT results_NNS suggest_VBP that_IN a_DT tightly_RB
        membrane-associated_JJ regulatory_JJ subunit_NN of_IN the_DT α-secretase_JJ complex_NN is_VBZ likely_JJ to_TO be_VB the_DT key_JJ
        phosphoprotein_NN that_WDT mediates_NNS α-secretase_JJ activity_NN as_IN a_DT function_NN of_IN its_PRP$ state_NN of_IN
        phosphorylation_NN by_IN PKC_NNP and_CC perhaps_RB also_RB ERK_NNP and_CC ROCK_NNP 1_CD ._. The_DT molecular_JJ identity_NN of_IN this_DT
        phosphoprotein_NN remains_VBZ unknown_JJ ._.
        α-_NN Secretase_NNP activation_NN is_VBZ a_DT potential_JJ therapeutic_JJ strategy_NN for_IN modifying_VBG cerebral_JJ
        amyloidosis_NNS in_IN Alzheimer_NNP disease_NN [_NN 66_CD ]_NN ._. This_DT proposal_NN is_VBZ supported_VBN by_IN recent_JJ evidence_NN that_IN
        either_DT genetic_JJ modification_NN of_IN ADAM-_NNP 10_CD /_NN α-secretase_JJ activity_NN [_NN 67_CD ]_NN or_CC administration_NN of_IN
        bryostatin_NN ,_, a_DT PKC_NNP activator_NN [_NN 68_CD ]_NN ,_, can_MD modulate_VBP levels_NNS of_IN brain_NN Aβ_NNP in_IN plaque-forming_JJ
        transgenic_JJ mice_NNS ._. α-_NN Secretase_NNP activation_NN may_MD explain_VB how_WRB statins_NNS lower_VB the_DT risk_NN for_IN
        Alzheimer_NNP disease_NN [_NN 69_CD ]_NN ,_, since_IN atorvastatin_NN diminishes_VBZ Aβ_NNP burden_NN in_IN plaque-forming_JJ
        transgenic_JJ mice_NNS [_NN 13_CD ]_NN ._. If_IN α-secretase_JJ stimulation_NN is_VBZ to_TO be_VB truly_RB viable_JJ as_IN a_DT human_JJ clinical_JJ
        intervention_NN ,_, it_PRP will_MD be_VB essential_JJ to_TO assess_VB the_DT possibility_NN that_WDT enhanced_VBD APP_NNP ectodomain_NN
        shedding_VBG might_MD incur_VB mechanism-based_JJ toxicity_NN (_( analogous_JJ to_TO the_DT concerns_NNS currently_RB
        surrounding_VBG γ-secretase_JJ inhibitors_NNS )_) ._. Along_IN this_DT line_NN ,_, extension_NN of_IN this_DT work_NN to_TO other_JJ shed_VB
        proteins_NNS will_MD be_VB important_JJ to_TO determine_VB the_DT impact_NN of_IN enhanced_VBN shedding_VBG via_IN ADAM_NNP
        proteinases_NNS on_IN other_JJ substrates_NNS of_IN those_DT proteinases_NNS ,_, including_VBG Notch_NNP ,_, pro-_JJ TGFα_NNP ,_, pro-_JJ TNFα_NNP ,_,
        and_CC CD_NNP 44_CD [_NN 3_CD ]_NN ._.
        Preliminary_JJ results_NNS from_IN a_DT pilot_NN proof-of-concept_JJ using_VBG atorvastatin_NN in_IN a_DT human_JJ clinical_JJ
        treatment_NN trial_NN are_VBP consistent_JJ with_IN the_DT proposed_VBN beneficial_JJ effects_NNS of_IN this_DT class_NN of_IN
        compounds_NNS [_NN 70_CD ]_NN ._. Since_IN atorvastatin_NN has_VBZ low_JJ blood–brain_NN barrier_NN permeability_NN [_NN 71_CD ]_NN ,_, this_DT
        beneficial_JJ effect_NN ,_, if_IN attributable_JJ to_TO Aβ_NNP lowering_VBG ,_, must_MD be_VB due_JJ to_TO altered_VBN Aβ_NNP metabolism_NN in_IN
        the_DT periphery_NN ._. Reduction_NNP in_IN levels_NNS of_IN free_JJ Aβ_NNP in_IN the_DT circulation_NN has_VBZ been_VBN demonstrated_VBN to_TO
        lead_VB to_TO diminution_NN in_IN brain_NN plaque_NN burden_NN following_VBG active_JJ or_CC passive_JJ immunization_NN [_NN 72_CD ]_NN ._. It_PRP
        is_VBZ conceivable_JJ that_IN ,_, if_IN statins_NNS lower_JJR circulating_VBG Aβ_NNP ,_, this_DT effect_NN could_MD secondarily_RB cause_VB
        diffusion_NN of_IN central_JJ nervous_JJ system_NN interstitial_NN Aβ_NNP down_RP its_PRP$ concentration_NN gradient_NN and_CC
        into_IN the_DT cerebrospinal_NN fluid_NN and_CC circulation_NN ,_, from_IN which_WDT it_PRP is_VBZ cleared_VBN ._. To_TO date_NN ,_, however_RB ,_,
        this_DT mechanism_NN is_VBZ not_RB supported_VBN by_IN data_NNS from_IN human_JJ clinical_JJ trials_NNS ,_, where_WRB statin_NN
        administration_NN has_VBZ shown_VBN no_DT consistent_JJ effect_NN on_IN levels_NNS of_IN circulating_VBG or_CC cerebrospinal_NN
        fluid_JJ Aβ_NNP [_NN 73_CD ]_NN ._.
        The_DT results_NNS reported_VBD here_RB point_NN to_TO several_JJ areas_NNS for_IN additional_JJ investigation_NN ._. As_IN
        described_VBD above_IN ,_, the_DT key_JJ substrate_NN or_CC substrates_NNS linking_VBG cytoplasmic_JJ protein_NN
        phosphorylation_NN to_TO intralumenal_NN or_CC cell-surface_JJ protelysis_NNS remain_VBP to_TO be_VB identified_VBN ._.
        Nonetheless_RB ,_, α-secretase_JJ activation_NN has_VBZ been_VBN validated_JJ as_IN a_DT viable_JJ therapeutic_JJ strategy_NN for_IN
        modulating_VBG cerebral_JJ amyloidosis_NNS [_NN 67_CD ]_NN ._. Identification_NNP of_IN the_DT role_NN of_IN the_DT Rho_NNP /_NN ROCK_NNP pathway_NN in_IN
        regulating_VBG α-secretase_JJ provides_VBZ a_DT new_JJ avenue_NN for_IN its_PRP$ therapeutic_JJ activation_NN ,_, even_RB though_IN
        the_DT potential_JJ relevance_NN of_IN atorvastatin-mediated_JJ ROCK_NNP 1_CD inhibition_NN in_IN neurons_NNS may_MD not_RB
        explain_VB the_DT apparent_JJ clinical_JJ benefits_NNS of_IN the_DT drug_NN ._. Still_RB ,_, if_IN the_DT reported_VBN
        disease-modifying_JJ effect_NN of_IN atorvastatin_NN is_VBZ confirmed_VBN in_IN the_DT National_NNP Institute_NNP on_IN Aging_NNP 's_POS
        large_JJ ,_, multi-center_JJ trial_NN of_IN simvastatin_NN ,_, one_CD or_CC more_JJR compounds_NNS of_IN this_DT class_NN may_MD be_VB among_IN
        the_DT first_JJ disease-modifying_JJ compounds_NNS approved_VBN by_IN the_DT Food_NNP and_CC Drug_NNP Administration_NNP for_IN
        slowing_VBG the_DT progression_NN of_IN Alzheimer_NNP disease_NN ._.
      
      
        Supporting_VBG Information_NNP
        
          Accession_NNP Numbers_NNPS
          The_DT GenBank_NNP (_( http_NN :_: /_NN /_NN www_NN ._. ncbi_NN ._. nlm_NN ._. nih_NN ._. gov_NN /_NN Genbank_NNP /_NN )_) accession_NN numbers_NNS for_IN the_DT proteins_NNS
          discussed_VBN in_IN this_DT paper_NN are_VBP ROCK_NNP 1_CD (_( NP_NNP __NN 005397_CD )_) and_CC APP_NNP 695_CD ,_, 595_CD –_NN 596_CD KM_NNP /_NN NL_NNP (_( NP_NNP __NN 958817_CD )_) ._.
        
      
    
  
